(p=0.1). The treatment groups did not differ significantly by current age or length of
follow-up in years.
Figure 2 shows a comparison of PAR scores at DCF (debond) for all subjects used
in the analysis at each individual timepoint. There were no statistically significant
differences at debond between treatment groups, as measured by PAR scores, of subjects
used in the analysis at each individual timepoint. All subjects evaluated at each timepoint
essentially finished comprehensive treatment with no differences in PAR score between
early treatment groups.
LOI
S--
CI
0 m
Sn n n n
d I n 2 U W
|I ) n I T i T n In
BCH BCH BCH BCH BCH BCH BCH
DC F DC R1 DC R2 DC R3 DC R4 DC R5 DC R6
Subjects used for Analysis at each Timepoint
Figure 2. Comparison of PAR scores between treatment groups at debond (DCF).
B=Bionator, C=Control, H=Headgear/Biteplane. Medians, inter-quartile
ranges and outliers are shown. There are no significant differences between
treatment groups at DCF for all subjects used in the analysis.